immunotherapies

Research in Review

Trastuzumab Cost Effectiveness Varies Based on Hormone Receptor Status

09/06/2016

JCP Editors

How cost effective trastuzumab is for human epidermal growth factor receptor 2 (HER2)-positive breast cancer depends largely on patients’ age and hormone receptor status, according to a review published in PLOS...

How...

09/06/2016

Journal of Clinical Pathways

Research in Review

Treatment Combination Improves NSCLC Survival and Response

08/12/2016

JCP Editors

East Asian patients with advanced nonsquamous non-small cell lung cancer (NSCLC) and epidermal growth factor receptor mutations may benefit from treatment with pemetrexed plus gefitinib, results from a phase II...

East...

08/12/2016

Journal of Clinical Pathways

Research in Review

Ipilimumab Combination Significantly Improves Melanoma Outcomes

07/27/2016

JCP Editors

Ipilimumab (Yervoy; Bristol-Myers Squibb) combined with local peripheral treatments such as radiotherapy or electrochemotherapy may significantly prolong survival in patients with melanoma compared with...

...

07/27/2016

Journal of Clinical Pathways

Research in Review

Cost-Effectiveness of Two NSCLC Treatments Compared

07/15/2016

JCP Editors

Compared with docetaxel, nivolumab is not a cost-effective treatment option for nonsquamous non-small cell lung cancer unless its price is reduced or it is used after programmed death ligand 1 (PD-L1) testing,...

...

07/15/2016

Journal of Clinical Pathways

Interview

Immunotherapies and the Future of Cancer Care

03/08/2016

Five years ago, at the American Society of Clinical Oncology (ASCO) Annual Meeting (June 3-7, 2011; Chicago, IL), investigators presented data on the immunotherapy drug ipilimumab, the first treatment to improve...

Five...

03/08/2016

Journal of Clinical Pathways